

Chapter 224

Systemic Glucocorticoids

Victoria P. Werth

REFERENCES

1. Hench PS et al: The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone (compound E)) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. *Mayo Clin Proc* **24**:181, 1949
2. Esteban NV et al: Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. *J Clin Endocrinol Metab* **72**:39, 1991
3. Bloom E et al: Nuclear binding of glucocorticoid receptors: Relations between cytosol binding, activation and the biological response. *J Steroid Biochem* **12**:175, 1980
4. Flower RJ, Rothwell NJ: Lipocortin-1: Cellular mechanisms and clinical relevance. *Trends Pharmacol Sciences* **15**:71, 1994
5. Pepinsky RB et al: Five distinct calcium and phospholipid binding proteins share homology with lipocortin I. *J Biol Chem* **263**:10799, 1988
6. Wallner BP et al: Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. *Nature* **320**:77, 1986
7. Adcock IM, Ito K: Molecular mechanisms of corticosteroid actions. *Monaldi Archives for Chest Disease* **55**:256, 2000
8. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids—New mechanisms for old drugs. *N Engl J Med* **353**:1711, 2005
9. Buttgerit F et al: The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. *Scand J Rheumatol* **18**:103, 2005
10. Lu NZ, Cidlowski JA: The origin and functions of multiple human glucocorticoid receptor isoforms. *Ann N Y Acad Sci* **1024**:102, 2004
11. Croxtall JD, Choudhury Q, Flower RJ: Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. *Br J Pharmacol* **130**:289, 2001
12. Buttgerit F, Wehling M, Burmester GR: A new hypothesis of modular glucocorticoid actions. *Arthr Rheum* **41**:761, 1998
13. Groner B et al: Transcription initiation of transfected mouse mammary tumor virus LTR DNA is regulated by glucocorticoid hormones. *Nucleic Acids Res.* **11**:4713, 1983
14. Schacke H, Rehwinkel H, Asadullah K: Dissociated glucocorticoid receptor ligands: Compounds with an improved therapeutic index. *Curr Opin Invest Drugs* **6**:503, 2005
15. Rosen J, Miner JN: The search for safer glucocorticoid receptor ligands. *Endocrine Rev* **26**:452, 2005
16. Cupps TR, Fauci AS: Corticosteroid-mediated immunoregulation in man. *Immunol Rev* **65**:133, 1982
17. Stobie L et al: The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. *Proc Natl Acad Sci USA* **97**:8427
18. Goulding NJ et al: Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. *Inflam Res* **47**(Suppl. 3):S158, 1998
19. Liles WC, Dale DC, Klebanoff SJ: Glucocorticoids inhibit apoptosis of human neutrophils. *Blood* **86**:3181, 1995
20. Amano Y, Lee SW, Allison AC: Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: Mediation by decreased mRNA stability. *Mol Pharmacol* **43**:176, 1993
21. Kitajima T et al: A novel mechanism of glucocorticoid-induced immune suppression: The inhibition of T cell-mediated terminal maturation of a murine dendritic cell line. *J Clin Invest* **98**:142, 1996
22. Balow JE, Rosenthal AS: Glucocorticoid suppression of macrophage migration inhibitory factor. *J Exp Med* **137**:1031, 1973
23. Hogan MM, Vogel SN: Inhibition of macrophage tumoricidal activity by glucocorticoids. *J Immunol* **140**:513, 1988
24. Parrillo JE, Fauci AS: Mechanisms of glucocorticoid action on immune processes. *Annual Rev Pharmacol Toxicol* **19**:179, 1979

25. Butler WT, Rossen RD: Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone. *J Clin Invest* **52**:2629, 1973
26. Baxter JD: Advances in glucocorticoid therapy. *Adv Int Med* **45**:317, 2000
27. Franchin G et al: Pulse steroids: How much is enough? *Autoimmun Rev* **5**:111, 2006
28. Sabir SM, Werth VP: Pulse glucocorticoids. *Dermatol Clin* **18**:437, 2000
29. Levis S, Altman R: Bone densitometry: Clinical considerations. *Arthr Rheum* **41**:577, 1998
30. Genta RM: Global prevalence of strongyloidiasis: Critical review with epidemiologic insights into the prevention of disseminated disease. *Rev Infect Dis* **11**:755, 1989
31. Cogan MG et al: Prevention of prednisone-induced negative nitrogen balance. Effect of dietary modification on urea generation rate in patients on hemodialysis receiving high-dose glucocorticoids. *Ann Intern Med* **95**:158, 1981
32. Hernandez-Diaz S, Rodriguez LA: Steroids and risk of upper gastrointestinal complications. *Am J Epidemiol* **153**:1089, 2001
33. Siegrist CA et al: Vaccination strategies for children with specific medical conditions: A paediatrician's viewpoint. *Eur J Pediatr* **156**(12):899, 1997
34. Piper JM et al: Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. *Ann Intern Med* **114**:735, 1991
35. Luo JC et al: Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy. *Br J Clin Pharmacol* **68**(2):252, 2009
36. Richter B et al: Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. *Endocrinol Metab Clin North Am* **31**:751, 2006
37. Grinspoon SK, Biller BM: Clinical review 62: Laboratory assessment of adrenal insufficiency. *J Clin Endocrinol Metab* **79**:923, 1994
38. Graber AL et al: Natural history of pituitary-adrenal recovery following long-term suppression with corticosteroids. *J Clin Endocrinol Metab* **25**:11, 1995
39. Baxter JD: Minimizing the side effects of glucocorticoid therapy. *Adv Int Med* **35**:173, 1990
40. Salem M et al: Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. *Annals Surg* **219**:416, 1994
41. Krasner AS: Glucocorticoid-induced adrenal insufficiency. *JAMA* **282**:671, 1999
42. Glowniak JV, Loriaux DL: A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. *Surgery* **121**:123, 1997
43. Yong SL et al: Supplemental perioperative steroids for surgical patients with adrenal insufficiency. *Cochrane Database Syst Rev* (4):CD005367, 2009
44. Hopkins RL, Leinung MC: Exogenous Cushing's syndrome and glucocorticoid withdrawal. *Endocrinol Metab Clin North Am* **34**:371, 2005
45. Williams LC, Nesbitt LT, Jr.: Update on systemic glucocorticosteroids in dermatology. *Dermatol Clin* **19**:63, 2001
46. Vittorio CC, Werth VP: Preventive techniques to limit glucocorticoid-induced side effects. *Adv Dermatol* **16**:273, 2001
47. Lukert BP, Raisz LG: Glucocorticoid-induced osteoporosis: Pathogenesis and management. *Ann Intern Med* **112**:352, 1990
48. Adachi JD et al: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. *N Engl J Med* **337**:382, 1997
49. Luengo M et al: Vertebral fractures in steroid dependent asthma and involutional osteoporosis: A comparative study. *Thorax* **46**:803, 1991
50. Reid IR, Heap SW: Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. *Arch Int Med* **150**:2545, 1990
51. Ton FN et al: Effects of low-dose prednisone on bone metabolism. *J Bone Miner Res* **20**:464, 2005
52. van Staa TP et al: Use of oral corticosteroids in the United Kingdom. *QJM* **93**(2):105, 2000
53. Rizzato G, Montemurro L: Reversibility of exogenous corticosteroid-induced bone loss. *Eur Respir J* **6**:116, 1993
54. Godschalk MF, Downs RW: Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. *J Bone Miner Res* **3**:113, 1988
55. Pons F et al: The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. *Br J Rheum* **34**:742, 1995
56. Buckley LM et al: Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. *J Rheumatol* **22**:1055, 1995

57. Solomon L: Idiopathic necrosis of the femoral head: Pathogenesis and treatment. *Can J Surg* 24:573, 1981
58. Zizic TM et al: Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. *Am J Med* 79:596, 1985
59. Glueck CJ et al: Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. *Clin Ortho & Related Res* 334:43, 1997
60. David DS, Grieco MH, Cushman P, Jr.: Adrenal glucocorticoids after twenty years. A review of their clinically relevant consequences. *J Chronic Dis* 22:637, 1970
61. Etxabe J, Vazquez JA: Morbidity and mortality in Cushing's disease: an epidemiological approach. *Clin Endocrinol (Oxf)* 40:479, 1994
62. Colao A et al: Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. *J Clin Endocrinol Metab* 84:2664, 1999
63. Dixon RB, Christy NP: On the various forms of corticosteroid withdrawal syndrome. *Am J Med* 68:224, 1980
64. Brown ES: Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. *Ann N Y Acad Sci* 1179:41, 2009
65. Gustavson LE, Benet LZ: Pharmacokinetics of natural and synthetic glucocorticoids. *The Actual Cortex*. Cornwall, England: Butterworth, 1985, p. 235
66. Bovomkitti S et al: Reversion and reversion rate of tuberculin skin reactions in correlation with the use of prednisone. *Dis Chest* 38:51, 1960
67. Aucott JN: Glucocorticoids and infection. *Endocrinol Metab Clin North Am* 23:655, 1994
68. Rennick GJ: Use of systemic glucocorticosteroids in pregnancy: Be alert but not alarmed. *Australas J Dermatol* 47:34, 2006
69. Allen DB: Growth suppression by glucocorticoid therapy. *Endocrinol Metab Clin North Am* 25:699, 1996
70. Hochberg Z: Mechanisms of steroid impairment of growth. *Horm Res* 58(Suppl. 1):33, 2002
71. Chavatte C et al: Glucocorticoid pharmacokinetics and growth retardation in children with renal transplants. *Pediatr Nephrol* 19(8):898, 2004
72. Grote FK et al: Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia. *Arch Dis Child* 91(1):56, 2006
73. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced O: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthr Rheum* 44:1496, 2001
74. Amin S et al: The role of vitamin D in corticosteroid-induced osteoporosis: A meta-analytic approach. *Arthr Rheum* 42:1740, 1999
75. de Nijs RN et al: Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: A review with meta-analysis of randomized controlled trials including organ transplantation studies. *Osteoporos Int* 15:589, 2004
76. Richy F et al: Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. *Calcif Tissue Int* 76:176, 2005
77. Lane NE: An update on glucocorticoid-induced osteoporosis. *Rheum Dis Clin N Am* 27:235, 2001
78. Hall GM et al: Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. *Arthr Rheum* 37:1499, 1994
79. Lukert BP, Johnson BE, Robinson RG: Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. *J Bone Miner Res* 7:1063, 1992
80. Rossouw JE et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 288:321, 2002
81. Gambrell RD: Prevention of endometrial cancer with progestogens. *Maturitas* 8:159, 1986
82. Khovidhunkit W, Shoback DM: Clinical effects of raloxifene hydrochloride in women. *Ann Intern Med* 130:431, 1999
83. MacAdams MR, White RH, Chipps BE: Reduction of serum testosterone levels during chronic glucocorticoid therapy. *Ann Intern Med* 104:648, 1986
84. Finkelstein JS et al: Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. *Ann Intern Med* 106:354, 1987
85. Reid IR et al: Testosterone therapy in glucocorticoid-treated men. *Arch Int Med* 156:1173, 1996
86. Crawford BA et al: Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. *J Clin Endocrinol Metab* 88:3167, 2003

87. Bhasin S et al: Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. *J Clin Endocrinol Met* 95:2536-2559, 2010
88. Reid DM et al: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. *J Bone Miner Res* 15(6):1006, 2000
89. Saag KG et al: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. *N Engl J Med* 339:292, 1998
90. Struys A, Snelder AA, Mulder H: Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. *Am J Med* 99:235, 1995
91. Adachi JD et al: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. *Arthr Rheum* 44:202, 2001
92. Adachi JD et al: A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. *J Rheumatol* 27:2424, 2000
93. Reid DM et al: Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. *Calcif Tissue Int* 69:242, 2001
94. Cohen S et al: Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum* 42:2309, 1999
95. Ringe JD et al: Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: Results from a long-term comparative study. *Osteoporos Int* 14(10):801, 2003.
96. Amin S et al: The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: A meta-regression. *J Bone Miner Res* 17:1512, 2002
97. Reid DM et al: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet* 373(9671):1253, 2009
98. Kennel KA, Drake MT: Adverse effects of bisphosphonates: Implications for osteoporosis management. *Mayo Clin Proc* 84(7):632, 2009
99. Lazarovici TS et al: Bisphosphonate-related osteonecrosis of the jaws: A single-center study of 101 patients. *J Oral Maxillofac Surg* 67(4):850, 2009
100. Merigo E et al: Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): A four-case report. *J Oral Path Med* 34:613, 2006
101. Durie BG, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates *N Engl J Med* 353:99, 2005
102. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. *N Engl J Med* 353:99, 2005
103. Marx RE et al: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. *J Oral Maxillofacial Surg* 63:1567, 2006
104. Khosla S et al: Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 22(10):1479, 2007
105. Sarin J, DeRossi SS, Akintoye SO: Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. *Oral Dis* 14(3):277, 2008
106. Cranney A et al: Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. *Cochrane Database of Syst Rev* (2):CD001983, 2000
107. Reid IR: Glucocorticoid-induced osteoporosis. *Bailliere's Clin Endocrinol Met* 14:279, 2000
108. Pun KK, Chan LW: Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. *Clin Therapeutics* 11:205, 1989
109. Silverman SL, Azria M: The analgesic role of calcitonin following osteoporotic fracture. *Osteoporos Int* 13:858, 2002
110. Knopp JA et al: Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: A systematic review of randomized, controlled trials. *Osteoporos Int* 16:1281, 2005
111. Quattrocchi E, Kourlas H: Teriparatide: A review. *Clin Therapeutics* 26:841, 2004
112. Lane NE et al: Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. *Osteoporos Int* 11:434, 2000

113. Lane NE et al: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. *J Bone Miner Res* **15**:944, 2000
114. Lane NE et al: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. *J Clin Invest* **102**:1627, 1998
115. Hodsman AB et al: Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. *Endocrine Rev* **26**:688, 2005
116. Kurland ES et al: The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)]. *Osteoporos Int* **15**:992, 2004
117. Cohen D, Adachi JD: The treatment of glucocorticoid-induced osteoporosis. *J Steroid Biochem Mol Biol* **88**:337, 2004
118. Franchimont N, Canalis E: Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. *Autoimmun Rev* **2**:224, 2003
119. Liu RH, Albrecht J, Werth VP: Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. *Arch Dermatol* **142**(1):37, 2006
120. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* **285**:2486, 2001
121. Anonymous: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* **339**:1349, 1998
122. Anonymous: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). *Lancet* **344**:1383, 1994
123. Sacks FM et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* **335**:1001, 1996
124. Mont MA et al: Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus. *Clin Ortho & Related Res* **334**:91, 1997

